Editors-in-Chief

Prof. David Kerr CBE MA MD DSc FRCP (Glasgow & London) FRCGP  FACP FESMO FMedSci, Radcliffe Department of Medicine, University of Oxford, UK
David contributes to Oxford as Professor of Cancer Medicine and Honorary Consultant medical oncologist, where he has worked with colleagues over the past 25 years to build a new Institute for Cancer Medicine and Cancer Hospital. He has an international reputation for the treatment of and research into colorectal cancer and the quality of his work has been recognised by the award of several national & international prizes, including the Tianfu Friendship Award (2022), the China Friendship Medal (2024), the Harvard Global Health Catalyst Distinguished Leader Award, in recognition of his many years of leadership in global health work. He was elected Fellow of the Academy of Medical Sciences (2000), the European Academy of Cancer Sciences (2004), Fellow of Royal Colleges of Physicians, Honorary Fellow of Royal College of General Practitioners (2007), Fellow of Association of Cancer Physicians (2018), Fellow of European Society of Medical Oncology (2022) (appointed Commander of the British Empire by Her Majesty the Queen (2002) and was elected President of the European Society of Medical Oncology in 2010.

Prof. Kang Zhang, PhD, Center for Biomedicine and Innovations at Faculty of Medicine, Macau University of Science and Technology, China
Kang Zhang, MD, PhD is the Professor and Director of Center for Biomedicine and Innovations at Faculty of Medicine, Macau University of Science and Technology.  Dr. Zhang obtained his M.D. with Magna Cum Laude honors from Harvard Medical School and MIT joint MD program and his PhD in genetics from Harvard University. He did his postdoctoral training also at Harvard.  He completed his residency in ophthalmology at Johns Hopkins University and his retina surgery fellowship at University of Utah. He was a faculty member at Johns Hopkins University, Cleveland Clinic Foundation, University of Utah, and University of California San Diego. Among his honors include AAAS fellow, fellow of American Institute for Medical and Biological Engineering, memberships in Association of American Physicians and American Society of Clinical Investigation; Outstanding Achievement Award of Chinese Ophthalmological Society, Burroughs Wellcome Clinical Scientist Award in Translational Research; Lew R. Wasserman Merit Award and Senior Investigator Award from Research to PreventBlindness; Johns Hopkins Medical Institutions Clinician Scientist Award, the World Ophthalmologist 100 Powerlist, American’s Top Ophthalmologists, Elsevier highly Cited Scholar (2019). Dr. Zhang has published over 200 peer-reviewed manuscripts in top peer-reviewed journals- covering a wide range of topics in genetics, epigenetics, stem cells, nano-engineering and 3D printing, clinical trials, and artificial intelligence. He has more than 26,000 citations and an h-index of 80. His discovery that HTRA1 is a major susceptibility gene for age-related macular degeneration is listed as one of “top-ten breakthroughs in 2006” by Science Magazine.

Prof. Yu-Quan Wei, PhD, National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West China Hospital, West China Medical School, Sichuan University, China 
Yu-quan Wei, Ph.D., Professor and Director of National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu. He was educated at West China University of Medical Sciences for a bachelor's degree in Medicine and a Master's Degree in Medicine, and educated at Kyoto University in Japan for Doctoral Degree. His major research interests include: targeted therapy, signal transduction, gene and cell therapy, and cancer vaccines. He has published more than 300 papers in international journals including Nat Med, Nat Commun, PNAS, Blood, Cancer Res, Clinic Cancer Res, J Immunol, and J Biol Chem, etc. He was selected as an academician of Chinese Academy of Sciences in 2003. He is now President of China Medicinal Biotech Association. He has served as an associate editor of Human Gene Therapy and Editorial Board Member of several International Journals.